GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoform Finland PLC (FRA:4YL) » Definitions » PB Ratio

Nanoform Finland (FRA:4YL) PB Ratio : 1.68 (As of Mar. 28, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Nanoform Finland PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-03-28), Nanoform Finland's share price is €1.18. Nanoform Finland's Book Value per Share for the quarter that ended in Dec. 2024 was €0.70. Hence, Nanoform Finland's PB Ratio of today is 1.68.

The historical rank and industry rank for Nanoform Finland's PB Ratio or its related term are showing as below:

FRA:4YL' s PB Ratio Range Over the Past 10 Years
Min: 1.47   Med: 2.81   Max: 81.82
Current: 1.69

During the past 9 years, Nanoform Finland's highest PB Ratio was 81.82. The lowest was 1.47. And the median was 2.81.

FRA:4YL's PB Ratio is ranked better than
62.64% of 1282 companies
in the Biotechnology industry
Industry Median: 2.395 vs FRA:4YL: 1.69

During the past 12 months, Nanoform Finland's average Book Value Per Share Growth Rate was -17.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -15.50% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 26.70% per year.

During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Nanoform Finland was 112.20% per year. The lowest was -15.50% per year. And the median was 52.10% per year.

Back to Basics: PB Ratio


Nanoform Finland PB Ratio Historical Data

The historical data trend for Nanoform Finland's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoform Finland PB Ratio Chart

Nanoform Finland Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
Get a 7-Day Free Trial Premium Member Only 7.34 5.58 2.79 1.86 1.91

Nanoform Finland Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.86 3.23 1.97 2.01 1.91

Competitive Comparison of Nanoform Finland's PB Ratio

For the Biotechnology subindustry, Nanoform Finland's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanoform Finland's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoform Finland's PB Ratio distribution charts can be found below:

* The bar in red indicates where Nanoform Finland's PB Ratio falls into.


;
;

Nanoform Finland PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Nanoform Finland's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2024)
=1.18/0.702
=1.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Nanoform Finland  (FRA:4YL) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Nanoform Finland PB Ratio Related Terms

Thank you for viewing the detailed overview of Nanoform Finland's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanoform Finland Business Description

Traded in Other Exchanges
Address
Cultivator II, Viikinkaari 4, Helsinki, FIN, 00790
Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceuticals pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications. Geographically, the company generates maximum revenue from Europe, followed by the United States and other regions.

Nanoform Finland Headlines

No Headlines